Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [5463]

The anti-CTLA-4 antibody ipilimumab targets regulatory T cells in melanoma patients

The anti-CTLA-4 antibody ipilimumab targets regulatory T cells in melanoma patients

Four subgroups defined for gastric cancer

Four subgroups defined for gastric cancer

Mouse models show tailored immunotherapy to be effective

Mouse models show tailored immunotherapy to be effective

AACR 2015: PARP inhibitor combo shows early promise for patients with and without BRCA mutations

AACR 2015: PARP inhibitor combo shows early promise for patients with and without BRCA mutations

AACR 2015: Antibody-drug conjugate shows early promise for patients with metastatic HER2-positive breast cancer

AACR 2015: Antibody-drug conjugate shows early promise for patients with metastatic HER2-positive breast cancer

AACR 2015: Dual mTOR inhibitor-fulvestrant combo feasible, with clinical benefit for advanced breast cancer patients

AACR 2015: Dual mTOR inhibitor-fulvestrant combo feasible, with clinical benefit for advanced breast cancer...

AACR 2015: Investigational ER degrader safe, with early signs of antitumour activity against advanced ER-positive breast cancer

AACR 2015: Investigational ER degrader safe, with early signs of antitumour activity against advanced ER-positive...

AACR 2015: Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma

AACR 2015: Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma

AACR 2015: Real-world targeted treatment based on whole genome sequencing difficult in pancreatic cancer

AACR 2015: Real-world targeted treatment based on whole genome sequencing difficult in pancreatic cancer

AACR 2015: Combining two investigational immunotherapy drugs safe, with early signs of effectiveness

AACR 2015: Combining two investigational immunotherapy drugs safe, with early signs of effectiveness

More from ecancer